🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

Recruitingn/aAges 19 Years - anyAllAbbVie
NCT06603558 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants with migraine suitable for the treatment with atogepant according to the latest approved local label. * Participants prescribed atogepant in accordance with the approved local label. Exclusion Criteria: * Participants with any contraindication to atogepant as listed on the latest approved local label. * Participants currently participating in another clinical research except observational study.
💊

What it tests

  • Atogepant
📍

Where

36 sites
On Hospital /ID# 285157
Busan, South Korea
Ryu Sang Hyo Neurosurgery Clinic /ID# 284804
Busan, South Korea
Dong-A University Medical Center /ID# 275321
Busan, South Korea
Chungnam National University Hospital /ID# 284724
Daejeon, South Korea
Chuncheon Sacred Heart Hospital /ID# 275315
Gangwon-do, South Korea
Chonnam National University Hospital /ID# 275318
Gwangju, South Korea
Korea University Ansan Hospital /ID# 284725
Ansan-si, South Korea
Inje University - Ilsan Paik Hospital /ID# 280738
Goyang, South Korea

…and 28 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy